Compile Data Set for Download or QSAR
Report error Found 32 Enz. Inhib. hit(s) with all data for entry = 2228
TargetOrexin receptor type 2(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM357847(2-{[(3R,6S)-6-(hydroxymethyl)- 1-{[2-(2H-1,2,3-tri...)
Affinity DataIC50: 8nMAssay Description:In a typical experiment the OX1 and OX2 receptor antagonistic activity of the compounds of the present invention was determined in accordance with th...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/20/2019
Entry Details
Go to US Patent

TargetOrexin receptor type 2(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM357851(2-{[(3R,6S)-6-(hydroxymethyl)- 1-{[2-(2,2,2-triflu...)
Affinity DataIC50: 9nMAssay Description:In a typical experiment the OX1 and OX2 receptor antagonistic activity of the compounds of the present invention was determined in accordance with th...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/20/2019
Entry Details
Go to US Patent

TargetOrexin receptor type 2(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM357848(2-{[(3R,6S)-6-(hydroxymethyl)- 1-{[2-(2H-1,2,3-tri...)
Affinity DataIC50: 11nMAssay Description:In a typical experiment the OX1 and OX2 receptor antagonistic activity of the compounds of the present invention was determined in accordance with th...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/20/2019
Entry Details
Go to US Patent

TargetOrexin receptor type 2(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM357850(US10214535, Example 10)
Affinity DataIC50: 12nMAssay Description:In a typical experiment the OX1 and OX2 receptor antagonistic activity of the compounds of the present invention was determined in accordance with th...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/20/2019
Entry Details
Go to US Patent

TargetOrexin receptor type 2(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM357854(2-{[(3R,6S)-(hydroxymethyl)- 1-{[2-(trifluorometho...)
Affinity DataIC50: 14nMAssay Description:In a typical experiment the OX1 and OX2 receptor antagonistic activity of the compounds of the present invention was determined in accordance with th...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/20/2019
Entry Details
Go to US Patent

TargetOrexin receptor type 2(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM357843(2-{[(3R,6S)-6-(hydroxymethyl)- 1-{[2-(2H-1,2,3-tri...)
Affinity DataIC50: 17nMAssay Description:In a typical experiment the OX1 and OX2 receptor antagonistic activity of the compounds of the present invention was determined in accordance with th...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/20/2019
Entry Details
Go to US Patent

TargetOrexin receptor type 2(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM357845([(2S,5R)-5-[(4-methylpyridin- 2-yl)oxy]-1-{[2-(2H-...)
Affinity DataIC50: 18nMAssay Description:In a typical experiment the OX1 and OX2 receptor antagonistic activity of the compounds of the present invention was determined in accordance with th...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/20/2019
Entry Details
Go to US Patent

TargetOrexin receptor type 2(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM357842(US10214535, Example 2)
Affinity DataIC50: 21nMAssay Description:In a typical experiment the OX1 and OX2 receptor antagonistic activity of the compounds of the present invention was determined in accordance with th...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/20/2019
Entry Details
Go to US Patent

TargetOrexin receptor type 2(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM357856(2-{[(3R,6S)-6-(1-hydrox-1- methylethyl)-1-{[2-(2H-...)
Affinity DataIC50: 27nMAssay Description:In a typical experiment the OX1 and OX2 receptor antagonistic activity of the compounds of the present invention was determined in accordance with th...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/20/2019
Entry Details
Go to US Patent

TargetOrexin receptor type 2(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM357852(2-{[(3R,6S)-6-(hydroxymethyl)- 1-{[2-(1-methyletho...)
Affinity DataIC50: 27nMAssay Description:In a typical experiment the OX1 and OX2 receptor antagonistic activity of the compounds of the present invention was determined in accordance with th...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/20/2019
Entry Details
Go to US Patent

TargetOrexin receptor type 2(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM357855(US10214535, Example 15)
Affinity DataIC50: 31nMAssay Description:In a typical experiment the OX1 and OX2 receptor antagonistic activity of the compounds of the present invention was determined in accordance with th...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/20/2019
Entry Details
Go to US Patent

TargetOrexin receptor type 2(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM357853(2-{[(3R,6S)-1-{[2- (difluoromethoxy)phenyl] carbon...)
Affinity DataIC50: 39nMAssay Description:In a typical experiment the OX1 and OX2 receptor antagonistic activity of the compounds of the present invention was determined in accordance with th...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/20/2019
Entry Details
Go to US Patent

TargetOrexin receptor type 2(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM357844(methyl 2-cyano-6-{[(3R,6S)-6- (hydroxymethyl)-1-{[...)
Affinity DataIC50: 49nMAssay Description:In a typical experiment the OX1 and OX2 receptor antagonistic activity of the compounds of the present invention was determined in accordance with th...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/20/2019
Entry Details
Go to US Patent

TargetOrexin receptor type 2(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM357846([(2S,5R)-5-{[4-(2,2- difluoroethoxy)pyridin-2-yl] ...)
Affinity DataIC50: 60nMAssay Description:In a typical experiment the OX1 and OX2 receptor antagonistic activity of the compounds of the present invention was determined in accordance with th...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/20/2019
Entry Details
Go to US Patent

TargetOrexin receptor type 2(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM357849([(2S,5R)-5-[(4-methylpyridin- 2-yl)oxy]-1-{[2-(2H-...)
Affinity DataIC50: 68nMAssay Description:In a typical experiment the OX1 and OX2 receptor antagonistic activity of the compounds of the present invention was determined in accordance with th...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/20/2019
Entry Details
Go to US Patent

TargetOrexin receptor type 2(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM357841(US10214535, Example 1)
Affinity DataIC50: 198nMAssay Description:In a typical experiment the OX1 and OX2 receptor antagonistic activity of the compounds of the present invention was determined in accordance with th...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/20/2019
Entry Details
Go to US Patent

TargetOrexin/Hypocretin receptor type 1(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM357856(2-{[(3R,6S)-6-(1-hydrox-1- methylethyl)-1-{[2-(2H-...)
Affinity DataIC50: 1.33E+3nMAssay Description:In a typical experiment the OX1 and OX2 receptor antagonistic activity of the compounds of the present invention was determined in accordance with th...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/20/2019
Entry Details
Go to US Patent

TargetOrexin/Hypocretin receptor type 1(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM357845([(2S,5R)-5-[(4-methylpyridin- 2-yl)oxy]-1-{[2-(2H-...)
Affinity DataIC50: 1.71E+3nMAssay Description:In a typical experiment the OX1 and OX2 receptor antagonistic activity of the compounds of the present invention was determined in accordance with th...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/20/2019
Entry Details
Go to US Patent

TargetOrexin/Hypocretin receptor type 1(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM357847(2-{[(3R,6S)-6-(hydroxymethyl)- 1-{[2-(2H-1,2,3-tri...)
Affinity DataIC50: 1.78E+3nMAssay Description:In a typical experiment the OX1 and OX2 receptor antagonistic activity of the compounds of the present invention was determined in accordance with th...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/20/2019
Entry Details
Go to US Patent

TargetOrexin/Hypocretin receptor type 1(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM357848(2-{[(3R,6S)-6-(hydroxymethyl)- 1-{[2-(2H-1,2,3-tri...)
Affinity DataIC50: 2.03E+3nMAssay Description:In a typical experiment the OX1 and OX2 receptor antagonistic activity of the compounds of the present invention was determined in accordance with th...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/20/2019
Entry Details
Go to US Patent

TargetOrexin/Hypocretin receptor type 1(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM357851(2-{[(3R,6S)-6-(hydroxymethyl)- 1-{[2-(2,2,2-triflu...)
Affinity DataIC50: 4.08E+3nMAssay Description:In a typical experiment the OX1 and OX2 receptor antagonistic activity of the compounds of the present invention was determined in accordance with th...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/20/2019
Entry Details
Go to US Patent

TargetOrexin/Hypocretin receptor type 1(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM357849([(2S,5R)-5-[(4-methylpyridin- 2-yl)oxy]-1-{[2-(2H-...)
Affinity DataIC50: 9.89E+3nMAssay Description:In a typical experiment the OX1 and OX2 receptor antagonistic activity of the compounds of the present invention was determined in accordance with th...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/20/2019
Entry Details
Go to US Patent

TargetOrexin/Hypocretin receptor type 1(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM357850(US10214535, Example 10)
Affinity DataIC50: 1.00E+4nMAssay Description:In a typical experiment the OX1 and OX2 receptor antagonistic activity of the compounds of the present invention was determined in accordance with th...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/20/2019
Entry Details
Go to US Patent

TargetOrexin/Hypocretin receptor type 1(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM357846([(2S,5R)-5-{[4-(2,2- difluoroethoxy)pyridin-2-yl] ...)
Affinity DataIC50: 1.00E+4nMAssay Description:In a typical experiment the OX1 and OX2 receptor antagonistic activity of the compounds of the present invention was determined in accordance with th...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/20/2019
Entry Details
Go to US Patent

TargetOrexin/Hypocretin receptor type 1(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM357852(2-{[(3R,6S)-6-(hydroxymethyl)- 1-{[2-(1-methyletho...)
Affinity DataIC50: 1.00E+4nMAssay Description:In a typical experiment the OX1 and OX2 receptor antagonistic activity of the compounds of the present invention was determined in accordance with th...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/20/2019
Entry Details
Go to US Patent

TargetOrexin/Hypocretin receptor type 1(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM357853(2-{[(3R,6S)-1-{[2- (difluoromethoxy)phenyl] carbon...)
Affinity DataIC50: 1.00E+4nMAssay Description:In a typical experiment the OX1 and OX2 receptor antagonistic activity of the compounds of the present invention was determined in accordance with th...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/20/2019
Entry Details
Go to US Patent

TargetOrexin/Hypocretin receptor type 1(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM357844(methyl 2-cyano-6-{[(3R,6S)-6- (hydroxymethyl)-1-{[...)
Affinity DataIC50: 1.00E+4nMAssay Description:In a typical experiment the OX1 and OX2 receptor antagonistic activity of the compounds of the present invention was determined in accordance with th...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/20/2019
Entry Details
Go to US Patent

TargetOrexin/Hypocretin receptor type 1(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM357854(2-{[(3R,6S)-(hydroxymethyl)- 1-{[2-(trifluorometho...)
Affinity DataIC50: 1.00E+4nMAssay Description:In a typical experiment the OX1 and OX2 receptor antagonistic activity of the compounds of the present invention was determined in accordance with th...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/20/2019
Entry Details
Go to US Patent

TargetOrexin/Hypocretin receptor type 1(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM357843(2-{[(3R,6S)-6-(hydroxymethyl)- 1-{[2-(2H-1,2,3-tri...)
Affinity DataIC50: 1.00E+4nMAssay Description:In a typical experiment the OX1 and OX2 receptor antagonistic activity of the compounds of the present invention was determined in accordance with th...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/20/2019
Entry Details
Go to US Patent

TargetOrexin/Hypocretin receptor type 1(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM357855(US10214535, Example 15)
Affinity DataIC50: 1.00E+4nMAssay Description:In a typical experiment the OX1 and OX2 receptor antagonistic activity of the compounds of the present invention was determined in accordance with th...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/20/2019
Entry Details
Go to US Patent

TargetOrexin/Hypocretin receptor type 1(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM357842(US10214535, Example 2)
Affinity DataIC50: 1.00E+4nMAssay Description:In a typical experiment the OX1 and OX2 receptor antagonistic activity of the compounds of the present invention was determined in accordance with th...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/20/2019
Entry Details
Go to US Patent

TargetOrexin/Hypocretin receptor type 1(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM357841(US10214535, Example 1)
Affinity DataIC50: 1.00E+4nMAssay Description:In a typical experiment the OX1 and OX2 receptor antagonistic activity of the compounds of the present invention was determined in accordance with th...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/20/2019
Entry Details
Go to US Patent